Reta and Elora strengthen Lilly's obesity leadership; J.P. Morgan reiterates Overweight

Overview

This is a J.P. Morgan ADA conference note on Eli Lilly & Company. The core view of the report is that retatrutide data and the investor meeting have widened Lilly's lead over competitors in the obesity and T2D market; meanwhile, eloralintide provides the company with a second important late-stage obesity pipeline asset.

Core views

The report believes high-dose retatrutide delivers best-in-class weight-loss efficacy, while the low dose combines efficacy close to Zepbound with better tolerability and faster titration, meaning the commercial opportunity may be broader than previously expected. With meaningful weight loss and a lower vomiting rate, eloralintide may play a role in patients with inadequate GLP-1 response, patients who prioritize tolerability, first-line treatment, and combination therapy. Overall, Lilly is well positioned to sustain and expand its leadership over the long term in the $200bn+ incretin/obesity market.

Analysis framework

The report mainly evaluates Lilly's obesity pipeline in terms of efficacy, tolerability, titration convenience, potential indications, and commercialization positioning based on clinical data disclosed at the ADA conference, company investor meeting information, cross-comparisons with existing products Zepbound and Mounjaro, and physician feedback on the amylin mechanism.

Methodology notes

• Clinical data interpretationEfficacy and tolerability trade-off

  Assess drug commercial positioning by combining indicators such as weight-loss magnitude, vomiting rate, AE-related discontinuation rate, and titration steps.

  High-dose retatrutide delivers stronger weight loss but has higher vomiting and discontinuation rates; the 4mg dose has efficacy close to Zepbound with faster titration, and therefore may broaden usage scenarios.

• Peer comparisonBest-in-class assessment

  Compare efficacy and tolerability against existing products such as Zepbound and Mounjaro.

  The report notes that 12mg retatrutide achieved 28.3% weight loss at 80 weeks, above about 21% for Zepbound; in T2D patients, weight loss was about 17%, above about 11% for Mounjaro.

• Pipeline value assessmentIndication and line-of-therapy positioning

  Evaluate a drug's potential market role as monotherapy, combination therapy, first-line treatment, or a treatment option for difficult-to-treat patients.

  Because eloralintide shows meaningful weight loss and a lower vomiting rate, it may cover patients with inadequate GLP-1 response, patients seeking better tolerability, and scenarios involving combination use with drugs such as tirzepatide.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Eli Lilly & Company (LLY.N)

  The company covered by the report and the investment rating target.

  Strengths

  Owns a multi-layered portfolio of metabolic drug assets including Zepbound, Mounjaro, retatrutide, and eloralintide; the pipeline is positioned to continue expanding in efficacy, tolerability, and use cases.

  Weaknesses

  High-dose retatrutide still involves trade-offs in vomiting rate and AE-related discontinuation rate, and future commercialization still depends on clinical, regulatory, and supply execution support.

  Comparison

  The report believes retatrutide has stronger efficacy than reference products Zepbound and Mounjaro, while eloralintide is superior to the GLP-1 class in vomiting tolerability.

  Risks

  Clinical data durability, regulatory approval, launch timing, competitor catch-up, and safety signals could all affect the investment thesis.

• retatrutide (Reta)

  Lilly's core late-stage obesity/T2D pipeline asset.

  Strengths

  The 12mg dose delivers nearly 30% weight loss, while the 4mg dose shows about 19% weight loss with faster titration, potentially covering both high-BMI and broader patient populations.

  Weaknesses

  The high-dose vomiting rate is 25%, with AE-related discontinuation at about 11%; urinary tract infection at 8-9% is a newly observed signal.

  Comparison

  High-dose weight loss exceeds Zepbound's roughly 21%, while weight loss in T2D patients at about 17% is above Mounjaro's roughly 11%; the 4mg dose is broadly comparable to high-dose Zepbound but titrates faster.

  Risks

  Tolerability, long-term safety, real-world adherence, and pre- and post-launch label restrictions.

• eloralintide (Elora)

  Lilly's second major obesity pipeline opportunity.

  Strengths

  About 16% weight loss at 48 weeks, with vomiting-related AEs meaningfully below the GLP-1 class; can be used as monotherapy, combination therapy, first-line treatment, or in patients with inadequate GLP-1 response.

  Weaknesses

  More ph2/ph3 data are still needed to validate efficacy and safety across different indications and combination regimens.

  Comparison

  Versus the GLP-1 class, the report emphasizes better vomiting tolerability; data on combination treatment with tirzepatide in T2D are a key area to watch next.

  Risks

  ph3 execution, combination therapy data, indication breadth, and uncertainty around regulatory and commercial positioning.

Key data

• Current ratingOverweightJ.P. Morgan reiterated OW in the report.
• Share price$1,131.42Price date is 2026-06-05.
• retatrutide 12mg weight loss28.3%Average body weight reduction at 80 weeks in the obesity study.
• retatrutide extension weight lossabout 30%Weight loss at 104 weeks among about 500 patients with baseline BMI >35, equivalent to about 80-85 pounds.
• retatrutide weight loss in T2D patientsabout 17%The report says this is meaningfully above other products, for example Mounjaro at about 11%.
• retatrutide 12mg vomiting rate25%Higher-dose efficacy is stronger, but tolerability involves a moderate trade-off.
• retatrutide 12mg AE discontinuation rateabout 11%Slightly above other injectable products.
• retatrutide 4mg weight lossabout 19%Low-dose performance is close to high-dose Zepbound.
• retatrutide 4mg vomiting rate and discontinuation rate10.6% / 4.1%And it requires only one 4-week titration.
• eloralintide weight lossabout 16%48-week data, with vomiting-related AEs below the GLP-1 class.
• Market size$200bn+The long-term incretin/obesity market opportunity referenced in the report.
• Key timelinesretatrutide 2027; eloralintide 2028The sequence of expected launches projected by the report.

Impact & implications

If clinical and commercialization progress proceeds smoothly, retatrutide could secure a strong position in high-BMI patients through greater weight-loss magnitude, while at lower doses it may expand usage through faster titration and better tolerability; eloralintide, meanwhile, adds a more tolerable and mechanistically differentiated amylin asset to Lilly's portfolio. Together, the two should help Lilly further raise the standard of obesity treatment and strengthen its product lineup in the long-term large-scale metabolic drug market.

Risks

• The vomiting rate for high-dose retatrutide is 25%, and the AE-related discontinuation rate is about 11%, which may affect use in some patients.
• An 8-9% urinary tract infection signal appeared in the retatrutide study. Although the report says most cases were mild, all resolved, and none led to discontinuation, this still requires further monitoring.
• The launch timelines of retatrutide in 2027 and eloralintide in 2028 are subject to clinical, regulatory, and commercial execution uncertainty.
• Competition in the obesity and T2D market is intense, and peer data, pricing, reimbursement, and production capacity could all affect long-term share.
• The report discloses potential conflicts of interest, including J.P. Morgan's market-making, investment banking, shareholding, and client relationships with Eli Lilly & Company.

What to watch

• Subsequent regulatory progress for retatrutide, label scope, and the potential 2027 launch timeline.
• Real-world tolerability, discontinuation rates, and patient segmentation usage across different retatrutide doses.
• ph3 program design, enrollment progress, and indication coverage for eloralintide.
• ph2 data in 2H26 for eloralintide combined with tirzepatide in T2D patients.
• Changes in efficacy, supply, pricing, and reimbursement for Zepbound, Mounjaro, and competing products in the obesity treatment market.